	US 12,460,006 B2
	Antibodies against integrin alpha 11 beta 1
Elma Kurtagic, Milton, MA (US); James W. Meador, III, Needham, MA (US); and Christopher Beneduce, Jr., Medford, MA (US)
Assigned to Momenta Pharmaceuticals, Inc., Titusville, NJ (US)
Appl. No. 17/757,607
Filed by Momenta Pharmaceuticals, Inc., Titusville, NJ (US)
PCT Filed Dec. 18, 2020, PCT No. PCT/US2020/066107 § 371(c)(1), (2) Date Jun. 17, 2022, PCT Pub. No. WO2021/127500, PCT Pub. Date Jun. 24, 2021.
Claims priority of provisional application 63/054,717, filed on Jul. 21, 2020.
Claims priority of provisional application 62/983,155, filed on Feb. 28, 2020.
Claims priority of provisional application 62/951,723, filed on Dec. 20, 2019.
Prior Publication US 2023/0050972 A1, Feb. 16, 2023
Int. Cl. C07K 16/28 (2006.01); A61P 1/16 (2006.01); A61P 11/00 (2006.01); A61P 35/00 (2006.01); C12N 15/63 (2006.01)

CPC C07K 16/2842 (2013.01) [A61P 1/16 (2018.01); A61P 11/00 (2018.01); A61P 35/00 (2018.01); C12N 15/63 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01)]

9 Claims

1. An anti-integrin alpha 11 beta 1 (α11β1) antibody, or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises: (1) a heavy chain comprising a heavy chain complementarity determining region 1 (CDRH1), a heavy chain complementarity determining region 2 (CDRH2), and a heavy chain complementarity determining region 3 (CDRH3) and (2) a light chain comprising a light chain complementarity determining region 1 (CDRL1), a light chain complementarity determining region 2 (CDRL2), and a light chain complementarity determining region 3 (CDRL3), and wherein

the CDRH1 comprises the sequence GYTFTSYG (SEQ ID NO: 439),

the CDRH2 comprises the sequence ISAYNGNT (SEQ ID NO: 265),

the CDRH3 comprises the sequence VTGITGTTIDP (SEQ ID NO: 267),

the CDRL1 comprises the sequence QSISSY (SEQ ID NO: 216),

the CDRL2 comprises the sequence DAS (SEQ ID NO: 269), and

the CDRL3 comprises the sequence QQYNNWPQT (SEQ ID NO: 271).